CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← CytoDyn Inc. (CYDY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

CytoDyn Inc. (CYDY)

Pharmaceutical Preparations · market cap $290M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
CytoDyn Inc. (CYDY) is a clinical-stage pharmaceutical company with a market cap of approximately $478M at $0.35/share and roughly 1.37 billion shares outstanding. Its lead asset is leronlimab (PRO 140), a humanized monoclonal antibody targeting CCR5, in Phase 3 development for HIV and earlier-stage trials in NASH, COVID-19, and oncology indications. The company carries only $15.7M in cash — roughly 3.8 months of runway — against $24.9M in net debt, with no near-term catalysts on the calendar and no sell-side analyst coverage.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
PRO 140 (humanized monoclonal antibody to CCR5)Phase 2HIV -1 Infection
Optimized Background RegimenPhase 3HIV
PRO 140Phase 3HIV-1-infection
LeronlimabPhase 2Solid Tumor, Adult
Price & technical context
3-month
+0.0%
6-month
-35.3%
12-month
-26.7%
52-wk range
$0.19–$0.37
vs 50-day MA
-0.5%
vs 200-day MA
-12.4%
Realized vol
65.9%
Max drawdown
-55.5%

Daily closes through 2026-11-20. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for CYDY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.